Friday, September 24, 2021 10:04:11 AM
Are you saying that Simufilam would have applications on "the entire family of CNS diseases, including the RARE 200+ listed?
Am I reading you right?
Would you happen to have ANY IDEA what they could collectively represent in terms of population?
Also I see Biogen's "treatment" is at $56,000.00/yr
Any idea of the $25-$30k figure is reasonable?
So far the best I could find is BABY BOOMERS pushing the total
number of those diagnosed with Alzheimer's UP from 44M to about 50M globally over the next few years & is said to continue for a decade or more.
Market Size: ~50M
Drug cost: ~$30k/yr
Total Market: ~$1.5T/yr
That does NOT include the 200 or so RARE CNS & other CNS applications if I read your post correctly.
Recent FLNA News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 09:16:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 12:10:21 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/28/2026 08:06:04 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/28/2026 08:04:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/28/2026 08:01:27 PM
